Display options
Cite
Havers F, Fry A, Peacock G, et al. Influenza vaccination and treatment in children with neurologic disorders. Ther Adv Vaccines. 2014;2(4):95-105doi: 10.1177/2051013613519217.
Havers, F., Fry, A., Peacock, G., & Finelli, L. (2014). Influenza vaccination and treatment in children with neurologic disorders. Therapeutic advances in vaccines, 2(4), 95-105. https://doi.org/10.1177/2051013613519217
Havers, Fiona, et al. "Influenza vaccination and treatment in children with neurologic disorders." Therapeutic advances in vaccines vol. 2,4 (2014): 95-105. doi: https://doi.org/10.1177/2051013613519217
Havers F, Fry A, Peacock G, Finelli L. Influenza vaccination and treatment in children with neurologic disorders. Ther Adv Vaccines. 2014 Jul;2(4):95-105. doi: 10.1177/2051013613519217. PMID: 24982759; PMCID: PMC4063242.
Copy Download .nbib Format: NLM
Share it on

Ther Adv Vaccines. 2014 Jul;2(4):95-105. doi: 10.1177/2051013613519217.

Influenza vaccination and treatment in children with neurologic disorders.

Therapeutic advances in vaccines

Fiona Havers, Alicia Fry, Georgina Peacock, Lyn Finelli

Affiliations

  1. MHS Influenza Division, Centers for Disease Control and Prevention, 1600 Clifton Road NE, MS A-32, Atlanta, GA 30333, USA.
  2. Centers for Disease Control and Prevention, Atlanta, Georgia, USA.

PMID: 24982759 PMCID: PMC4063242 DOI: 10.1177/2051013613519217

Abstract

Influenza viruses cause substantial morbidity in children each year, especially among children with specific chronic conditions. In particular, neurologic disorders have emerged as a strong risk factor for influenza-related complications. Children with these disorders may be vulnerable due to diminished respiratory muscle strength, decreased muscle tone or impaired mobility, which can compromise pulmonary function and the ability to handle secretions. Although they represent a small fraction of the general pediatric population, children with neurologic disorders make up a disproportionately high number of those children who are hospitalized and die as a result of influenza-associated complications. Annual vaccination is the most effective way to prevent influenza and its complications, and is recommended for all children 6 months through 18 years of age, including children with neurologic disorders. Family members and those who work with these children in institutional, educational and daycare settings should also be vaccinated against influenza annually. However, there have been few studies of influenza vaccination specifically in this population. In addition, vaccine effectiveness may vary from year to year and vaccination will not prevent all infections. Early empiric antiviral treatment should be started promptly in these children if they present to healthcare providers with symptoms suspicious for influenza. This article reviews influenza epidemiology in children with neurologic disorders and what is known about vaccines and other methods of protecting this vulnerable population from influenza-related complications.

Keywords: Influenza; influenza vaccination; neurologic disorders

References

  1. MMWR Recomm Rep. 2008 Aug 8;57(RR-7):1-60 - PubMed
  2. J Pediatr. 2007 Mar;150(3):306-10 - PubMed
  3. MMWR Morb Mortal Wkly Rep. 2013 Jun 14;62(23):473-9 - PubMed
  4. Vaccine. 2011 Jan 10;29(3):444-50 - PubMed
  5. MMWR Recomm Rep. 2005 Jul 29;54(RR-8):1-40 - PubMed
  6. N Engl J Med. 2005 Dec 15;353(24):2559-67 - PubMed
  7. Birth Defects Res A Clin Mol Teratol. 2010 Dec;88(12):1008-16 - PubMed
  8. Clin Infect Dis. 2014 Feb;58(3):319-27 - PubMed
  9. Vaccine. 2007 Jun 6;25(23):4521-4 - PubMed
  10. J Am Geriatr Soc. 2009 Sep;57(9):1580-6 - PubMed
  11. Pediatrics. 2013 Oct;132(4):e1089-104 - PubMed
  12. Cochrane Database Syst Rev. 2007 Jan 24;(1):CD002744 - PubMed
  13. Neurology. 2012 Oct 2;79(14):1474-81 - PubMed
  14. N Engl J Med. 2006 Jul 6;355(1):31-40 - PubMed
  15. JAMA. 2005 Nov 2;294(17):2188-94 - PubMed
  16. Pediatrics. 2011 Dec;128(6):e1450-8 - PubMed
  17. Spine J. 2009 Dec;9(12):981-6 - PubMed
  18. Res Dev Disabil. 2011 Mar-Apr;32(2):462-9 - PubMed
  19. MedGenMed. 2007 Oct 30;9(4):23 - PubMed
  20. Pediatr Infect Dis J. 2001 Feb;20(2):127-33 - PubMed
  21. J Child Neurol. 2013 May;28(5):596-601 - PubMed
  22. Pediatr Infect Dis J. 2006 Jun;25(6):572 - PubMed
  23. Vaccine. 2011 Oct 26;29(46):8323-9 - PubMed
  24. Pediatrics. 2013 Feb;131(2):207-16 - PubMed
  25. Clin Infect Dis. 2010 Dec 15;51(12):e95-104 - PubMed
  26. MMWR Surveill Summ. 2012 Mar 30;61(3):1-19 - PubMed
  27. Int J Adolesc Med Health. 2009 Jan-Mar;21(1):79-89 - PubMed
  28. Pediatr Infect Dis J. 2011 Nov;30(11):962-6 - PubMed
  29. MMWR Recomm Rep. 2013 Sep 20;62(RR-07):1-43 - PubMed
  30. Int J Pediatr Otorhinolaryngol. 2010 Jun;74(6):684-8 - PubMed
  31. Neurology. 2005 Jan 11;64(1):13-20 - PubMed
  32. Pediatrics. 2009 Jul;124(1):170-8 - PubMed
  33. Arch Phys Med Rehabil. 2011 Jan;92(1):46-50 - PubMed
  34. Pediatrics. 2012 Sep;130(3):390-6 - PubMed
  35. Clin Infect Dis. 2011 Jan 1;52 Suppl 1:S69-74 - PubMed
  36. Infect Control Hosp Epidemiol. 2013 Jul;34(7):717-22 - PubMed
  37. Lancet. 2000 Jan 8;355(9198):93-7 - PubMed
  38. Vaccine. 2011 Nov 8;29(48):9005-11 - PubMed
  39. Vaccine. 2006 May 8;24(19):4096-101 - PubMed
  40. MMWR Morb Mortal Wkly Rep. 2012 Jan 6;60(51-52):1729-33 - PubMed
  41. Lancet. 2007 Mar 31;369(9567):1056 - PubMed
  42. J Allergy Clin Immunol. 2004 Apr;113(4):717-24 - PubMed
  43. JAMA. 2004 Sep 15;292(11):1333-40 - PubMed
  44. MMWR Recomm Rep. 2011 Jan 21;60(1):1-24 - PubMed
  45. Pediatr Infect Dis J. 2010 Jun;29(6):495-8 - PubMed
  46. BMJ. 2003 Jun 7;326(7401):1235 - PubMed
  47. Adv Ther. 2012 Oct;29(10):826-48 - PubMed
  48. Pediatrics. 2007 Apr;119(4):740-8 - PubMed
  49. MMWR Morb Mortal Wkly Rep. 2013 Sep 13;62(36):744-6 - PubMed

Publication Types